ESMO Open

Article	Citations
Editorial Board	301
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)	212
Editorial Board	183
87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience	131
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression	124
Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer	118
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches	118
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors	115
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines	109
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap	106
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles	103
225P Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients	94
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study	93
ESMO	88
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f	87
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials	86
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)	85
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling	85
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada	84
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)	84
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study	80
Editorial Board	77
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations	77
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group	75
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes	75

62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio	74
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas	74
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma	72
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC	71
Editorial Board	69
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma	68
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–2020	62
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy	61
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer	60
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cance	59
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection	57
199P Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)	56
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells	56
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response	55
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis	55
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib	54
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US	53
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study	52
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer	50
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot	50
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations	49
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom	49
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials	48
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients	48
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?	47
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage	47
74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis	46
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study	46
175P Quality of life in patients with NSCLC brain metastases undergoing different local therapies in the era of precision oncology: A territory-wide study	46
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study	46
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study	44
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations	44
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats	43
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.	43
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia	43
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies	42
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat	42
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers	42
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication	42
Table of Contents	41
27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target	41
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients	41
143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 2024	40
Table of Contents	40
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas	40
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer	40
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study	39
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas	39
Table of Contents	38
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX	38

137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts	38
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopaus	38
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology	38
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer	37
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids	37
144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy	36
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer	36
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]	35
Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials	35
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cance	34
Refining patient selection for breast cancer immunotherapy: beyond PD-L1	34
Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: developme	34
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the rando	34
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review	34
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study	34
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced	34
48P An AI System for accurate Ki-67 IHC assessment in breast cancer following the IKWG whole section global scoring protocol	33
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities	33
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results	33
PP474 Isoliensinine enhances therapeutic efficacy of paclitaxel and induces mitochondria-mediated cell death in multidrug-resistant colon cancer stem cells	33
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study	33
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies	32
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single	32
Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series	32
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes	32
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer	32
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)	31
Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients	31
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial	31
An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore	30
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers	30
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer	30
Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores	30
Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)	29
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial	29
Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019	29
103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience	29
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	29
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study	28
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts	28
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets	28
Psychiatric disorders in adolescent and young adult cancer survivors in Korea	27
108P Biomarkers and personalized cancer therapy: A study of trial discontinuation and unpublished rates	27
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting	27
23P Anti-tumor activity of novel Globo-H targeting CAR T cells in cholangiocarcinoma model	27
Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors	26
131P Symptoms, fear of cancer recurrence and supportive care needs in gastrointestinal stromal tumor patients undergoing targeted therapy	26
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis	26
Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’	26
The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma	26
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phas	26
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments	26
6P vAO - Variant Annotator for OncoKB: A simplified interface to identify targeted therapies for somatic tumors	26
52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)	25
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab	25
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes	25
Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Ital	25
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A	25
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis	25
Collagen signature adds prognostically significant information to staging for breast cancer	25
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer	25
7P Unveiling the prognostic significance of protein expression in advanced high-grade serous ovarian cancer: A comparative study between long-term survivors and early mortal patients	25
89P Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients	24
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study	24
21P Squamous cell carcinoma arising from germ cell tumour of the ovary treated with immunotherapy	24
59P Delay in diagnosis of soft tissue sarcoma (STS): Contributing factors and their impact on overall survival - Experience from a tertiary care hospital	24
Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs	24
108P Unravelling how different treatment sequences affect survival in osteosarcoma patients: A population-based study	24
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis	24
45P Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence	24
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer	24
44P Reintroduction of platinum-based chemotherapy ± mitotane for advanced adrenocortical cancer: Single-center retrospective trial	24
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study	23
53P Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation	23
11P Conization before radical hysterectomy in early cervical cancer: A Korean multi-center study	23
29P First-line of camrelizumab, apatinib mesylate and chemotherapy for advanced high-grade neuroendocrine tumors (NETS): A single center, single arm, exploratory study	23
117P Merkel cell carcinoma: Epidemiological pattern in the United States, a SEER based study	23
14P Unravelling the immune landscape of non-epithelial ovarian cancer	23
132P Novel small molecule modulators for activation of mutant tumor suppressor p53	23
17P Exploiting the immune-modulatory effects of PI3K/mTOR inhibitors to enhance response to immune-checkpoint blockade in uterine leiomyosarcoma	23

Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?	22
153P Discovery of new BRCA1/2 mutations not described in the international breast consortium	22
142P Exploring 18F-FDG PET as a predictior of immune-related adverse events (irAEs) in early-stage triple-negative breast cancer (eTNBC)	22
Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical O	22
73P TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma	22
154P Alternative splicing in non-small cell lung cancer evolution	22
94P Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes	22
Corrigendum to ‘A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-	22
152P Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping	22
46P The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis	22
272P Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial - The ADAPT study	21
268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation	21
296P Management of sexual dysfunction in breast cancer survivor women on adjuvant therapy	21
54P Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment	21
93P Intra- and post-operative management of sentinel lymph node micrometastasis and prognosis analysis in patients with breast cancer from southern China: A multicenter, retrospective, real-world stud	21
224P Efficacy of single-agent second-line fulvestrant (FUL) in metastatic invasive lobular carcinoma (mILC) exposed to first-line aromatase inhibitors (AI) and cyclin-dependent kinase 4 and 6 inhibito	21
Editorial Board	21
243P Identifying the communication needs of people living with metastatic breast cancer (MBC) in Ireland: An all-Ireland patient-led survey (CTRIAL-IE 23-05)	21
16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer	20
83P Radiological evaluation of response in patients with soft tissue sarcoma treated with trabectedin	20
297P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective	20
5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study	20
54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression	20
208P The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC	20
233P Real-world first-line (1L) treatment selection for Australian patients (pts) with hormone receptor-positive advanced breast cancer (HR+ ABC)	20
17P Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs	20
96P Age-adjusted trends and survival analysis of alveolar soft part sarcoma	20
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)	20
18P AURKB inhibition radiosensitises NSCLC by altering mitotic fate	19
18P PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response	19
139P Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis	19
161P DESCARTES trial: De-ESCAlating RadioTherapy in patients with pathologic complete response to neoadjuvant systemic therapy	19
252P Characterization of sexual dysfunction in women with lung cancer: Update of the CLARIFY project	19
108P Establishing a multi-modal tissue preparation and imaging workflow to study heterogeneity in neuroblastoma tumors	19
PP065 In silico genetic polymorphisms analysis of GSTP1 and their effect on platinum compound and antituberculosis drugs co-medication in lung cancer patients with tuberculosis comorbidity	18
58P The lymphocyte activation gene-3 (LAG-3) protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma	18
PP067 Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients	18
OP28 Cost-effectiveness analyses of durvalumab consolidation therapy compared to no consolidation therapy after definitive chemoradiotherapy in stage III NSCLC	18
258TiP A phase II trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or met	18
PP064 MicroRNA 200c-3p targeting CDH1 gene polymorphism towards risk susceptibility of prostate cancer in North Indian population	18
263P Cross-sectional nationwide population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: A study of the French	18
PP215 Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the type of EGFR activating mutations and agents in non-small cell lung cancer (NSCLC): A real-world study	18
80P Efficacy, FDA approval, innovativeness, clinical evidence, and price of breast, ovarian, endometrial, and cervical cancer drugs	18
14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status	18
90P Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients? A real-life study	18
PP108 Is it possible to avoid seroma after mastectomy and axillary lymph node dissection using microporous polysaccharide hemispheres (AristaTM)?	18
77P The impact of COVID-19 on gynecological cancer diagnoses in Greece	18
PP499 3-weekly daratumumab-based quadruplet induction regimen is highly effective in newly diagnosed multiple myeloma	17
114P Effects of chemotherapy on TREG lymphocytes in early breast cancer	17
58P Evaluating the impact of WGTS in routine diagnostics of bone and soft tissue tumors	17
205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer	17
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Ther	17
151TiP TANGENT: A phase III, global, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor	17
33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models	17
142P Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis	17
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers	17
Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer	17
A qualitative study on the challenges health care professionals face when caring for adolescents and young adults with an uncertain and/or poor cancer prognosis	17
Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)	17
76P Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression	17
79P Real-world comparative analysis of liposomal doxorubicin and paclitaxel in first-line treatment of Kaposi sarcoma: A retrospective study in Brazil	17
153P BRAF variants and therapy outcomes in melanoma	17
Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors	17
Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer	17
Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure	17
Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients	16
ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology	16
107P Treatment landscape in SDH-deficient gastrointestinal stromal tumors: A systematic review and meta-analysis	16
Professor Gouri Shankar Bhattacharyya	16
29P Exploring the risk of second primary malignancies in head and neck versus non-head and neck small cell carcinoma survivors	16
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology	16
109P Prognostic significance of pan-immune inflammation value (PIV) in predicting metastasis in patients with gastrointestinal stromal tumors	16
54P Survival outcomes and clinicopathological features of rectal neuroendocrine tumors: A retrospective analysis from a Latin American cohort	16
162MO Long-term development of 12- and 15-year-old offspring after maternal cancer during pregnancy: A prospective multicentre cohort study	16
Table of Contents	16
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma	16
89P Duchenne muscular dystrophy gene product expression is associated with survival in sarcoma	16
31P A global examination of clinical trials for patients with salivary gland cancers: An in-depth review of international registries and current challenges	16
188O EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine the	15
Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors	15
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups	15
Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries	15
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer	15
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study	15
Disparities of birth cohort effects on pancreatic cancer incidence between the United States and urban China	15
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational coho	15
Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis	15
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)	15
Androgen receptor pathway inhibitors and drug–drug interactions in prostate cancer	15
Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study	15
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of rando	15
Insomnia in adult patients with cancer: ESMO Clinical Practice Guideline	15
Table of Contents	15
56P Rapid and accurate prediction of TKI treatment response in advanced EGFR-mutant non-small cell lung cancer using the CODRP platform	14
56P Prevalence, clinical characteristics, and treatment outcomes of patients with KRAS-mutated non-squamous NSCLC and PD-L1 expression: Real-life data analysis	14